Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies

By LabMedica International staff writers
Posted on 30 Mar 2026

Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining molecular signature. More...

A newly certified assay now provides the first IVDR-certified option in the European Union for IGH clonality detection.

The IdentiClone Dx IGH Assay from Invivoscribe (San Diego, CA, USA) has received European Union In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification. It is described as the first IVDR-certified assay for detecting clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. BSI (Netherlands), an EU-designated Notified Body, granted CE certification following an independent conformity assessment. Commercial availability of the IVDR-certified assay is anticipated by early April 2026.

The assay is a PCR-based in vitro diagnostic designed for capillary electrophoresis-based detection of clonality in IGH gene rearrangements from peripheral blood specimens. It now includes integrated analysis software that automates data processing and interpretation. The software provides standardized, objective results with transparent reporting and full traceability.

IdentiClone Dx IGH serves as an adjunctive tool in evaluating patients suspected of having B-cell lymphoproliferative disorders, in which expansion of a single B-cell clone creates identical (clonal) IGH rearrangements that are a molecular hallmark of B-cell malignancies. Under IVDR, in vitro diagnostic devices are classified from Class A (lowest risk) to Class D (highest risk). Class C devices, such as this assay, are considered high-risk tests that play a critical role in disease diagnosis and patient management. This approval represents Invivoscribe’s second successful IVDR certification.

“Achieving IVDR certification for the IdentiClone Dx IGH Assay is a significant milestone for Invivoscribe and reflects decades of regulatory rigor, scientific excellence, and dedication to international standards,” said Jason Gerhold, Vice President of Global Regulatory, Quality, and Clinical Affairs at Invivoscribe. “This certification demonstrates our ability to meet the most stringent regulatory requirements and positions us to continue supporting laboratories and clinicians across the EU with high-quality, compliant diagnostic solutions.”

Related Links
Invivoscribe


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Urine Analyzer
respons® UDS100
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.